- ►nih.gov GA Calin, CM Croce - Journal of Clinical Investigation, 2007 - Am Soc Clin Investig Currently, one in four deaths in the United States is due to cancer (1).
Therefore, every major pathogenetic, diagnostic or therapeutic advance has the
potential to save many lives. With the recent discovery of thousands of ... Cited by 45 - Related articles - BL Direct - All 7 versions
HM Kantarjian, F Giles, A Quintas-Cardama, J … - Clinical Cancer Research, 2007 - AACR Results: Imatinib, which targets the ABL kinase activity of BCR-ABL, has
prolonged survival in CML. Despite the efficacy of imatinib, some patients in
chronic phase and more in advanced phases of CML develop resistance, ... Cited by 35 - Related articles - BL Direct - All 5 versions
M Savona, M Talpaz - Nature Reviews Cancer, 2008 - medscape.com Tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukaemia (CML) is
the consummate success story for targeted therapy, yet relapse is a nearly
inevitable consequence of cessation or interruption of therapy. Primitive ... Cited by 28 - Related articles - BL Direct - All 7 versions
T Maekawa, E Ashihara, S Kimura - International Journal of Clinical Oncology, 2007 - Springer T. Maekawa (*) · E. Ashihara · S. Kimura Department of Transfusion Medicine
and Cell Therapy, Kyoto University Hospital, 54 Kawahara-cho, Shogoin, Sakyo-ku
606-8507, Japan Tel. +81-75-751-3628; Fax +81-75-751-3631 e-mail: ... Cited by 15 - Related articles - BL Direct - All 3 versions
E Jabbour, JE Cortes, H Ghanem, S OBrien, … - Expert Review of Anticancer Therapy, 2008 - ingentaconnect.com Chronic myeloid leukemia (CML) is characterized by the formation of the
Philadelphia chromosome and oncogenic signaling by the resulting Bcr–Abl
fusion protein. Understanding the molecular basis of CML has led to the ... Cited by 16 - Related articles - BL Direct - All 8 versions
L Kujawski, M Talpaz - Leukemia & Lymphoma, 2007 - informahealthcare.com Imatinib was the first treatment for chronic myeloid leukemia (CML) that
specifically targeted the causative BCR-ABL oncoprotein, and represented a major
therapeutic advance in this disease; however, some patients develop ... Cited by 13 - Related articles - BL Direct - All 5 versions
- ►nih.gov SJ Zhang, LY Ma, QH Huang, G Li, BW Gu, XD … - Proceedings of the National Academy of Sciences, 2008 - National Acad Sciences Acquisition of additional genetic and/or epigenetic abnormalities other than the
BCR/ABL fusion gene is believed to cause disease progression in chronic myeloid
leukemia (CML) from chronic phase to blast crisis (BC). To gain insights ... Cited by 13 - Related articles - BL Direct - All 6 versions
D Brazma, C Grace, J Howard, JV Melo, T … - Genes Chromosomes and Cancer, 2007 - interscience.wiley.com The expression of the chimeric BCR/ABL1 fusion gene resulting from t(9;22)(q34;
q11) in chronic myelogenous leukemia (CML) is necessary for malignant
transformation, but not sufficient to maintain disease progression. The ... Cited by 13 - Related articles - BL Direct - All 3 versions
J Gora-Tybor, T Robak - Current medicinal chemistry, 2008 - ingentaconnect.com Department of Hematology, Medical University of Lodz and Copernicus Memorial
Hospital, 93-510 Lodz, Ciolkowskiego 2, Poland Abstract: Chronic myeloid
leukemia (CML) is characterized by the presence of the Philadelphia (Ph) ... Cited by 10 - Related articles - All 4 versions
- ►nih.gov S Li - Leukemia & lymphoma, 2008 - Informa Pharma Science The BCR-ABL kinase inhibitor imatinib has shown significant efficacy in chronic
myeloid leukemia (CML) and is the standard front-line therapy for patients in
chronic phase. However, a substantial number of patients are either ... Cited by 10 - Related articles - BL Direct - All 9 versions
